If Virginia Kraus is prepared to go on a webinar and encourage OA sufferers to remain optimistic that a pharmaceutical solution to their pain and function may emerge sooner rather than later, perhaps she was spruiking her predictive Biomarker OA blood test, but perhaps an avenue to market exists for safe effective drugs with an unmet need. We were given Fast Track by the FDA, that means they acknowledge OA has an unmet medical need and that ZILOSUL has potential to meet that need.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
43.0¢ |
Change
-0.035(7.53%) |
Mkt cap ! $170.8M | |||
| Open | High | Low | Value | Volume |
| 47.0¢ | 47.5¢ | 42.0¢ | $676.1K | 1.519M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 16161 | 43.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 44.5¢ | 19584 | 1 |
View Market Depth
| Last trade - 16.10pm 07/07/2025 (20 minute delay) ? |
| PAR (ASX) Chart |